Ascendis Pharma A/S

- The company completed the full redemption of all outstanding convertible senior notes in May, indicating no current debt fundraising. - In Q1 2026, net finance expense was primarily noncash, with net cash financial expense around EUR 1 million, showing manageable interest costs. - The firm ended Q1 2026 with EUR 573 million in cash and equivalents, reflecting strong liquidity. - In April, the company transitioned to a direct listing on NASDAQ to broaden global investment access, potentially enhancing institutional ownership and trading liquidity. - There was no mention of any forthcoming equity fundraising; the focus is on sustaining R&D investment using existing capital. - Scott Smith highlighted prioritizing capital allocation towards R&D to sustain long-term growth beyond 2030s. - Further updates on capital allocation or fundraising are expected after the Q2 call.

- The company emphasizes continued investment in R&D as a key component of their capital allocation strategy. - Focus is on sustaining innovation and new product development into the 2030s and beyond. - New chemical entities (NCEs) are being highlighted as important upcoming areas. - Post-Q2 call, the company plans to provide more detailed guidance on outlook and capital allocation. - No specific mention of substantial capital expenditures (capex) or strategic capital investments beyond R&D at this time. - Capital allocation priorities currently favor R&D to support long-term growth and product pipeline expansion.

- Continued steady underlying increase in patients on therapy for YORVIPATH, driving strong sequential growth expected in Q2 and beyond. - SKYTROFA revenues expected to remain stable throughout 2026, following similar seasonal patterns as 2025. - Early demand for YUVIWEL is encouraging, with over 60 prescriptions in less than 5 weeks post-launch, suggesting strong growth potential. - Expansion opportunities for YORVIPATH include higher doses (up to 60 micrograms in the U.S.), geographic expansion, and label extensions to new patient groups (ages 8, 12 to 18). - Long-term confidence due to large patient populations: 70,000 to 90,000 with chronic hypoparathyroidism in the U.S. and 5-10 times more globally. - Steady patient enrollment and stable prescription growth expected, supported by improved insurance approval rates and faster reimbursement times. - Pipeline expansion with multiple new clinical trials supports sustained revenue growth into the 2030s and beyond.

- Q1 2026 operating profit was EUR 25 million with a 10% operating margin; non-IFRS operating profit was EUR 55 million, with a 22% margin. - As revenues scale, meaningful improvement in operating margin is expected over 2026 and beyond. - Non-IFRS net profit for Q1 2026 was EUR 18 million, or EUR 0.27 per share. - Strong revenue growth projected for YORVIPATH driven by steady patient enrollment and improved insurance approvals. - SKYTROFA expected to have stable revenue through 2026 following seasonal patterns. - Encouraging early demand for YUVIWEL suggests growth potential. - Continuous steady enrollment of new patients (~1,000 per quarter) expected to sustain growth. - Capital allocation prioritizes sustained R&D investment to support product pipeline and long-term growth into the 2030s and 2040s. - More detailed outlook to be provided after Q2 2026 results.

- The company has not explicitly stated a current or expected orderbook or pending orders value. - However, they reported strong demand trends, for example: - Over 60 prescriptions of YUVIWEL in less than 4–5 weeks since launch. - More than 1,000 new patients prescribed YORVIPATH in Q1 2026. - Over 6,300 patients prescribed YORVIPATH in the U.S. as of March 2026. - Insurance approval rates for U.S. products are improving, with a cumulative approval rate approaching mid-70%. - Enrollment and prescription trends are described as steady and growing, supporting a strong foundation for revenue growth. - The company plans to share more detailed updates on growth and guidance after the Q2 2026 call.